Zhao Gu

BD Head at Synvida Bio

Presenter

Synvida is an early stage biotech dedicated to the innovative drug development in the field of coagulation and hemostasis diseases and interdisciplinary areas. Founded by Professor Liu Junling, Former Vice-President of School of Basic Medicine of SJTUSM/SHSMU, who has been deeply involved in this field for over twenty years, he has accumulated rich experience in translational medicine and the discovery of new molecules. Synvida has three proprietary drug development platforms and has established multiple innovative drug R&D pipelines. Synvida recently completed a Series A financing of nearly 200 million CNY, and the funds will be used to advance the clinical and preclinical research of the existing pipelines. The company has achieved excellent results in the 11th China Innovation and Entrepreneurship Competition, winning honors such as "Excellent Enterprise of China Innovation and Entrepreneurship Competition." The vision of Synvida is to become an innovative source of Chinese pharmaceutical technology and a pillar of the national medical and health industry. Through industry-university-research cooperation, it accelerates the process of new drug development, bringing more effective treatment options to patients